Cargando…
Antiarrhythmic Effects of Carvedilol and Flecainide in Cardiomyocytes Derived from Catecholaminergic Polymorphic Ventricular Tachycardia Patients
Mutations in the cardiac ryanodine receptor (RYR2) are the leading cause for catecholaminergic polymorphic ventricular tachycardia (CPVT). In this study, we evaluated antiarrhythmic efficacy of carvedilol and flecainide in CPVT patient-specific induced pluripotent stem cell-derived cardiomyocytes (i...
Autores principales: | Pölönen, R. P., Penttinen, K., Swan, H., Aalto-Setälä, K. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5924967/ https://www.ncbi.nlm.nih.gov/pubmed/29760739 http://dx.doi.org/10.1155/2018/9109503 |
Ejemplares similares
-
The Antiarrhythmic Mechanisms of Flecainide in Catecholaminergic Polymorphic Ventricular Tachycardia
por: Li, Yukun, et al.
Publicado: (2022) -
Antiarrhythmic Effects of Dantrolene in Patients with Catecholaminergic Polymorphic Ventricular Tachycardia and Replication of the Responses Using iPSC Models
por: Penttinen, Kirsi, et al.
Publicado: (2015) -
Correction: Antiarrhythmic Effects of Dantrolene in Patients with Catecholaminergic Polymorphic Ventricular Tachycardia and Replication of the Responses Using iPSC Models
por: Penttinen, Kirsi, et al.
Publicado: (2015) -
Insights on the mechanism of flecainide in catecholaminergic polymorphic ventricular tachycardia
por: Davidson, Ross, et al.
Publicado: (2023) -
Questioning flecainide's mechanism of action in the treatment of catecholaminergic polymorphic ventricular tachycardia
por: Williams, Alan J., et al.
Publicado: (2016)